A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares

Parambir S. Dulai, Laura E. Raffals, David Hudesman, Michael Chiorean, Raymond Cross, Tasneem Ahmed, Michael Winter, Shannon Chang, David Fudman, Charlotte Sadler, Ernest L. Chiu, Frank L. Ross, Gary Toups, M. Hassan Murad, Kinjal Sethuraman, James R. Holm, Renie Guilliod, Benjamin Levine, Jay C. Buckey, Corey A. Siegel

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Hyperbaric oxygen has been reported to improve disease activity in hospitalised ulcerative colitis (UC) patients. Aim: To evaluate dosing strategies with hyperbaric oxygen for hospitalised UC patients. Methods: We enrolled UC patients hospitalised for acute flares (Mayo score 6-12). Initially, all patients received 3 days of hyperbaric oxygen at 2.4 atmospheres (90 minutes with two air breaks) in addition to intravenous steroids. Day 3 responders (reduction of partial Mayo score ≥ 2 points and rectal bleeding score ≥ 1 point) were randomised to receive a total of 5 days vs 3 days of hyperbaric oxygen. Results: We treated 20 patients with hyperbaric oxygen (75% prior biologic failure). Day 3 response was achieved in 55% (n = 11/20), with significant reductions in stool frequency, rectal bleeding and CRP (P < 0.01). A more significant reduction in disease activity was observed with 5 days vs 3 days of hyperbaric oxygen (P = 0.03). Infliximab or colectomy was required in only three patients (15%) despite a predicted probability of 80% for second-line therapy. Day 3 hyperbaric oxygen responders were less likely to require re-hospitalisation or colectomy by 3 months vs non-responders (0% vs 66%, P = 0.002). No treatment-related adverse events were observed. Conclusion: Hyperbaric oxygen appears to be effective for optimising response to intravenous steroids in UC patients hospitalised for acute flares, with low rates of re-hospitalisation or colectomy at 3 months. An optimal clinical response is achieved with 5 days of hyperbaric oxygen. Larger phase 3 trials are needed to confirm efficacy and obtain labelled approval.

Original languageEnglish (US)
Pages (from-to)955-963
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume52
Issue number6
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares'. Together they form a unique fingerprint.

Cite this